淋巴瘤自体造血干细胞移植中苯达莫司汀、依托泊苷、阿糖胞苷、美法仑 (BeEAM) 预处理方案的安全性.

BACKGROUND: In recent years, the application of new drugs such as monoclonal antibodies, small molecule targeted drugs and immunotherapy has significantly improved the short-term efficacy and long-term survival of patients with malignant lymphoma, but autologous hematopoietic stem cell transplantation still plays an important role in the overall treatment of malignant lymphoma. Preconditioning is a very important step in the whole process of autologous hematopoietic stem cell transplantation, but there is no standard preconditioning program at present. OBJECTIVE: To investigate the safety and effectiveness of Bendamustine, Etoposide, Cytarabine (Melphalan) BeEAM as preconditioning in autologous hematopoietic cell transplantation for patients with lymphomas. METHODS: From July 5, 2021 to May 31, 2022, 11 patients with lymphoma who underwent autologous hematopoietic stem cell transplantation with BeEAM preconditioning regimen in Department of Hematology of Henan Provincial People’s Hospital were enrolled in the study. The clinical characteristics, pretreatingrelated non-hematologic toxicity, and hematopoietic reconstitution of the patients were analyzed. RESULTS AND CONCLUSION: (1) The non-hematological toxicity of BeEAM pretreatment regimen mainly included oral mucositis, diarrhea and fever at granulosa stage, with the incidence of 72.7%, 63.6%, 90.9%, respectively. (2) The median time of neutrophil implantation was 9(8-11) days, and that of platelet implantation was 10(7-16) days. (3) BeEAM pretreatment regimen for autologous hematopoietic stem cell transplantation of lymphoma has controllable nonhematologic toxicity and rapid hematopoietic reconstruction, with transplant-related mortality of 0% at 100 days and transplant-related mortality of 0% at the end of follow-up period, showing good efficacy and safety. Chinese Clinical Trial Registry: identifier No. ChiCTR2100048295. [ABSTRACT FROM AUTHOR]